About NasVax
NasVax engages in the development of improved vaccines. Its technology platform is based on proprietary polycationic sphingolipid-derived molecules that serve both as a potent adjuvant for stimulating enhanced immune responses via the Th1 and Th2 pathways as well as an efficient delivery system. The platform enables intranasal as well as intramuscular and subcutaneous administrations and also may be applied to augment the bioactivity of established adjuvants and cytokines.
The Company's lead application is an improved formulation for influenza vaccine (Phase 1/2a) that has been shown in preclinical studies to be significantly more immunogenic and protective than a commercial influenza vaccine. In addition, preclinical studies with anthrax, avian flu and hepatitis B vaccines have demonstrated the increased potency of the adjuvant platform for both intramuscular and intranasal administrations.
The novel family of CSS lipids was co-developed by Professors Eli Kedar and Yechezkel Barenholz, a co-inventor of the anticancer drug that is marketed in the USA by Johnson & Johnson (as DoxilTM) and in Europe by Schering Plough (as Caelyx).
The Company was founded in August 2004 within the Meytav Technology Incubator and went public in December 2005.
- Focus : Manufacturer
- Industry : Pharma
